Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of kappa-opioid receptor (OPRK1) was performed using 70% confluent log phase PC-12 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with OPRK1 Rabbit Polyclonal Antibody (44-302G) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing membranous localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Mouse, Rat|
|Published species reactivity||Rat, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized peptide derived from the internal region of the mouse k-opioid receptor. The sequence is conserved in rat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 50% glycerol, 1mg/ml BSA|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Activation of the kappa-opioid receptor oppposes a variety of µ-opioid receptor mediated actions throughout the brain and spinal cord. In general, opioids modulate numerous central and peripheral processes, including pain perception, neuroendocrine secretion and the immune response. The opioid signal is transduced from receptors through G proteins to various different effectors. Subsequent to G protein activation, several effectors are known to orchestrate the opioid signal. For example, activation of opioid receptors increases phosphatidylinositol turnover, activates K+ channels and reduces adenylyl cyclase and Ca++ channels activities.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
44-302G was used in western blot to study the effect of the cannabinoid receptor antagonist/inverse agonist rimonabant on the opioid system.
|Zádor F,Lénárt N,Csibrány B,Sántha M,Molnár M,Tuka B,Samavati R,Klivényi P,Vécsei L,Marton A,Vizler C,Nagy GM,Borsodi A,Benyhe S,Páldy E||Neuropharmacology (89:298)||2015|
|Rat||Not Cited||Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats.||Jolivalt CG,Jiang Y,Freshwater JD,Bartoszyk GD,Calcutt NA||Diabetologia (49:2775)||2006|
||Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats.||Jolivalt CG,Jiang Y,Freshwater JD,Bartoszyk GD,Calcutt NA||Diabetologia (49:2775)||2006|
K-OR-1; kappa 1; Kappa opioid receptor; kappa-1; kappa-type opioid receptor; KOR; KOR-1; Opiate receptor; Opiate receptor, kappa-1; Opioid receptor; Opioid receptor kappa; opioid receptor, kappa 1; opioid receptor, kappa 2; OPRK; OPRK1; Ork1
K-OR-1; KOR; KOR-1; MSL-1; OPRK; OPRK1; Oprk2; R21; Ror-d